Search

Your search keyword '"Ronzoni M"' showing total 377 results

Search Constraints

Start Over You searched for: Author "Ronzoni M" Remove constraint Author: "Ronzoni M"
377 results on '"Ronzoni M"'

Search Results

1. Do patients’ and referral centers’ characteristics influence multiple sclerosis phenotypes? Results from the Italian multiple sclerosis and related disorders register

5. Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies

6. Data monitoring roadmap. The experience of the Italian Multiple Sclerosis and Related Disorders Register

8. Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO

9. Data monitoring roadmap. The experience of the Italian Multiple Sclerosis and Related Disorders Register

12. Signs and symptoms of COVID-19 in patients with multiple sclerosis

13. Detection of disability worsening in relapsing-remitting multiple sclerosis patients: a real-world roving Expanded Disability Status Scale reference analysis from the Italian Multiple Sclerosis Register

14. Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial

16. Changes in body composition during neoadjuvant therapy can affect prognosis in rectal cancer patients: An exploratory study

17. Do patients' and referral centers' characteristics influence multiple sclerosis phenotypes? Results from the Italian multiple sclerosis and related disorders register

18. Signs and symptoms of COVID-19 in patients with multiple sclerosis

19. SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study

20. The Italian multiple sclerosis register

22. PD-009 Safety and efficacy of FOLFOXIRI with or without targeted agents as first-line treatment of selected elderly metastatic colorectal cancer patients: a pooled analysis of GONO studies

23. PO-1214 Toxicity profile of adjuvant hypofractionated Image-Guided Radiotherapy in biliary tract carcinoma

24. PO-1212 Outcome of adjuvant hypofractionated radiotherapy concomitant to chemotherapy in bile duct carcinoma

27. Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial

28. Detection of lung hypoperfusion in Covid-19 patients during recovery by digital imaging quantification

30. Detection of disability worsening in relapsing-remitting multiple sclerosis patients: a real-world roving Expanded Disability Status Scale reference analysis from the Italian Multiple Sclerosis Register

34. PD-0539: Chemo-modulation of rectal cancer pathological response: prediction of an early regression index

35. 402MO Final results of the CARACAS study: Randomized phase II trial of avelumab alone or with cetuximab for unresectable, locally advanced or metastatic squamous cell anal carcinoma progressed to at least one line of treatment

36. 399O Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in elderly patients: A subgroup analysis from TOSCA trial

39. Phase III trial comparing 3-6months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: Safety and compliance in the TOSCA trial

41. Prognostic and predictive role of body mass index (BMI) in metastatic colorectal cancer (mCRC): A pooled analisys of TRIBE and TRIBE-2 studies by GONO

42. Clinical impact of mucinous and poorly differentiated tumours on the outcome of patients with stage II colon cancer: A TOSCA subgroup analysis

43. Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies

44. Impact of age and gender on safety and efficacy of first-line FOLFOXIRI/bevacizumab in mCRC: a pooled analysis of TRIBE and TRIBE2 studies

45. EP-1459 Impact of sentinel lymph-node biopsy and FDG-PET in staging and radiation treatment of anal cancer

46. PO-0816 Adaptive radiotherapy concomitant with chemotherapy as preoperative treatment for rectal cancer

47. Activity and safety of cetuximab plus modified folfoxiri followed by maintenance with cetuximab or bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer a randomized phase 2 clinical trial

48. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study

50. Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO

Catalog

Books, media, physical & digital resources